Drug Trial Radar · NCT04935476
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Nov 22, 2021
Primary completion
Mar 31, 2022
Study completion Jul 31, 2022
Sponsor
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pulmonem Inc.
- First posted
- Jun 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity, among those with confirmed SARS-CoV-2 infection. 3000 infected patients diagnosed with COVID-19, non-hospitalized at the time of enrollment, meeting all inclusion and no exclusion criteria will be randomized (1:1 allocation ratio) to receive either Dapsone or placebo tablets for 21 days, and will be followed up for 7 days after treatment termination for outcome assessment and up to 30 days for safety monitoring.
Conditions
- COVID-19
Interventions
Dapsone 85 mg PO BIDDrug
Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
Placebo 85 mg PO BIDDrug
Placebo oral tablet, twice daily for 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite outcome: All cause pre-hospitalization death or all-cause hospitalizationTime frame: 30 days post randomization
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Pulmonary and Medical Specialists
Phoenix, Arizona · Not yet recruiting
Peters Medical Research, LLC
High Point, North Carolina · Recruiting
Temple University Hospital
Philadelphia, Pennsylvania · Not yet recruiting
University of Pittsburgh UPMC
Pittsburgh, Pennsylvania · Not yet recruiting
Principle Research Solutions
Spokane, Washington · Recruiting
Inspiration Research Limited
Toronto, Ontario, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.